Ramírez David, Arévalo Bárbara, Martínez Gonzalo, Rinné Susanne, Sepúlveda Francisco V, Decher Niels, González Wendy
Centro de Bioinformática y Simulación Molecular, Universidad de Talca , 1 poniente No. 1141, 3460000 Talca, Chile.
Instituto de Ciencias Biomédicas, Universidad Autonoma de Chile , 5 Poniente No. 1670, 3460000 Talca, Chile.
Mol Pharm. 2017 Jul 3;14(7):2197-2208. doi: 10.1021/acs.molpharmaceut.7b00005. Epub 2017 May 30.
A1899 is a potent and selective inhibitor of the two-pore domain potassium (K) channel TASK-1. It was previously reported that A1899 acts as an open-channel blocker and binds to residues of the P1 and P2 regions, the M2 and M4 segments, and the halothane response element. The recently described crystal structures of K channels together with the newly identified side fenestrations indicate that residues relevant for TASK-1 inhibition are not purely facing the central cavity as initially proposed. Accordingly, the TASK-1 binding site and the mechanism of inhibition might need a re-evaluation. We have used TASK-1 homology models based on recently crystallized K channels and molecular dynamics simulation to demonstrate that the highly potent TASK-1 blocker A1899 requires binding to residues located in the side fenestrations. Unexpectedly, most of the previously described residues that interfere with TASK-1 blockade by A1899 project their side chains toward the fenestration lumina, underlining the relevance of these structures for drug binding in K channels. Despite its hydrophobicity, A1899 does not seem to use the fenestrations to gain access to the central cavity from the lipid bilayer. In contrast, binding of A1899 to residues of the side fenestrations might provide a physical "anchor", reflecting an energetically favorable binding mode that after pore occlusion stabilizes the closed state of the channels.
A1899是双孔域钾(K)通道TASK-1的一种强效且选择性的抑制剂。此前有报道称,A1899作为一种开放通道阻滞剂,与P1和P2区域、M2和M4片段以及氟烷反应元件的残基结合。最近描述的钾通道晶体结构以及新发现的侧窗表明,与TASK-1抑制相关的残基并非如最初所提出的那样纯粹面向中央腔。因此,TASK-1结合位点和抑制机制可能需要重新评估。我们使用基于最近结晶的钾通道的TASK-1同源模型和分子动力学模拟来证明,强效的TASK-1阻滞剂A1899需要与位于侧窗中的残基结合。出乎意料的是,大多数先前描述的干扰A1899对TASK-1阻断作用的残基将其侧链伸向窗腔,突出了这些结构在钾通道药物结合中的相关性。尽管A1899具有疏水性,但它似乎并未利用侧窗从脂质双层进入中央腔。相反,A1899与侧窗残基的结合可能提供一个物理“锚定”,反映出一种能量上有利的结合模式,在孔道堵塞后稳定通道的关闭状态。